Douglas R Martin Selected Research

GM2 Gangliosidoses (GM2 Gangliosidosis)

1/2020	Natural history study of glycan accumulation in large animal models of GM2 gangliosidoses.
1/2016	Animal models of GM2 gangliosidosis: utility and limitations.
1/2015	Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease.
1/2014	Ganglioside storage diseases: on the road to management.
5/2009	Neurodegenerative lysosomal storage disease in European Burmese cats with hexosaminidase beta-subunit deficiency.
11/2005	Mutation of the GM2 activator protein in a feline model of GM2 gangliosidosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Douglas R Martin Research Topics

Disease

9	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 11/2007
9	GM1 Gangliosidosis (Gangliosidosis GM1) 01/2022 - 06/2008
9	Sandhoff Disease (Sandhoff's Disease) 01/2021 - 03/2009
6	Lysosomal Storage Diseases (Lysosomal Storage Disease) 01/2021 - 05/2009
6	GM2 Gangliosidoses (GM2 Gangliosidosis) 01/2020 - 11/2005
4	Tay-Sachs Disease 01/2022 - 01/2015
4	Gangliosidoses (Gangliosidosis) 01/2016 - 05/2004
3	Disease Progression 01/2022 - 01/2015
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Obesity 01/2022
1	Seizures (Absence Seizure) 01/2022
1	Overweight 01/2022
1	Neoplasms (Cancer) 01/2022
1	Nervous System Diseases (Neurological Disorders) 01/2022
1	Insulin Resistance 01/2022
1	Body Weight (Weight, Body) 01/2022
1	Gliosis 12/2020
1	Type 2 Diabetes Mellitus (MODY) 01/2020
1	Infertility (Sterility) 01/2020
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2020
1	Alzheimer Disease (Alzheimer's Disease) 01/2020
1	Stroke (Strokes) 04/2014
1	Parkinson Disease (Parkinson's Disease) 04/2014
1	Ataxia (Dyssynergia) 11/2005

Drug/Important Bio-Agent (IBA)

10	EnzymesIBA 01/2021 - 06/2008
7	G(M2) Ganglioside (Ganglioside GM2)IBA 01/2021 - 05/2004
6	GalactosidasesIBA 01/2022 - 09/2012
3	LipidsIBA 01/2022 - 03/2009
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2015
3	Hexosaminidases (Hexosaminidase)IBA 01/2020 - 05/2009
3	GangliosidesIBA 01/2020 - 01/2014
3	beta-N-AcetylhexosaminidasesIBA 05/2009 - 05/2004
2	Hexosaminidase A (Hex A)IBA 01/2022 - 01/2018
2	bis(monoacylglyceryl)phosphateIBA 01/2020 - 05/2015
2	G(M1) GangliosideIBA 09/2012 - 06/2008
2	Proteins (Proteins, Gene)FDA Link 06/2008 - 05/2004
2	Complementary DNA (cDNA)IBA 06/2008 - 06/2008
2	beta-Galactosidase (Lactaid)IBA 06/2008 - 06/2008
1	Indicators and Reagents (Reagents)IBA 01/2022
1	PrebioticsIBA 01/2022
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 12/2020
1	Islet Amyloid PolypeptideIBA 01/2020
1	OligosaccharidesIBA 01/2020
1	Peptides (Polypeptides)IBA 01/2020
1	Polysaccharides (Glycans)IBA 01/2020
1	VaccinesIBA 01/2020
1	Amyloid (Amyloid Fibrils)IBA 01/2020
1	pramlintide (Symlin)FDA Link 01/2020
1	feralIBA 01/2020
1	SphingolipidsIBA 09/2017
1	GlycolipidsIBA 09/2017
1	Lysergic Acid Diethylamide (LSD)IBA 01/2017
1	Glycoside Hydrolases (Endoglycosidases)IBA 01/2016
1	Fatty Acids (Saturated Fatty Acids)IBA 05/2015
1	GlycosphingolipidsIBA 03/2009
1	Glucose (Dextrose)FDA LinkGeneric 06/2008
1	Protein Disulfide-IsomerasesIBA 06/2008
1	Arginine (L-Arginine)FDA Link 06/2008
1	G(M2) Activator ProteinIBA 11/2005
1	Amino Acids FDA Link 05/2004

Therapy/Procedure

8	Therapeutics 01/2022 - 11/2007
1	Aftercare (After-Treatment) 01/2022
1	Contraception (Birth Control) 01/2020
1	Investigational Therapies (Experimental Therapy) 01/2016
1	Enzyme Replacement Therapy 06/2008
1	Transplantation 11/2007